{"result": "(\"entity\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Sociedad Española de Endocrinología y Nutrición is an organization that published a manual on endocrinology and nutrition, including guidelines for the treatment of neuroendocrine tumors.)\n##\n(\"entity\"<|>MEN1<|>EVENT<|>MEN1 is a syndrome associated with multiple endocrine neoplasia, which increases the risk of developing various tumors, including neuroendocrine tumors.)\n##\n(\"entity\"<|>ENETS<|>ORGANIZATION<|>The European Neuroendocrine Tumor Society (ENETS) is an organization that provides guidelines and recommendations for the treatment of neuroendocrine tumors.)\n##\n(\"entity\"<|>NANETS<|>ORGANIZATION<|>The North American Neuroendocrine Tumor Society (NANETS) is an organization that focuses on the treatment and research of neuroendocrine tumors.)\n##\n(\"entity\"<|>VALDÉS GALLEGO N.<|>PERSON<|>Valdés Gallego N. is an author who contributed to the manual on endocrinology and nutrition, specifically on multiple endocrine neoplasia.)\n##\n(\"entity\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>EVENT<|>The Williams Textbook of Endocrinology is a comprehensive reference book on endocrinology, including information on multiple endocrine neoplasia.)\n##\n(\"entity\"<|>NEW ENGLAND JOURNAL OF MEDICINE<|>EVENT<|>The New England Journal of Medicine is a medical journal that published research on the increased risk of breast cancer in women with MEN1.)\n##\n(\"relationship\"<|>VALDÉS GALLEGO N.<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Valdés Gallego N. authored a chapter in the manual published by the Sociedad Española de Endocrinología y Nutrición<|>7)\n##\n(\"relationship\"<|>MEN1<|>ENETS<|>ENETS provides guidelines for the management of patients with MEN1 syndrome<|>8)\n##\n(\"relationship\"<|>MEN1<|>NANETS<|>NANETS offers recommendations for the treatment of patients with MEN1 syndrome<|>8)\n##\n(\"relationship\"<|>MEN1<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>The Williams Textbook of Endocrinology discusses MEN1 and its implications in endocrine tumors<|>6)\n##\n(\"relationship\"<|>MEN1<|>NEW ENGLAND JOURNAL OF MEDICINE<|>The New England Journal of Medicine published findings related to the risks associated with MEN1<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ab. 2012;97:1-22.\n- Valdés Gallego N. Manual de Endocrinología y Nutrición (Internet). Capítulo 3. Neoplasia Endocrina Múltiple. Madrid: Sociedad Española de Endocrinología y Nutrición; 2015. Disponible en: https://manual.seen.es.\n\n## Casos clínicos. Caso clínico 1\n\n### 42. En este caso, la cirugía está indicada:\n\nA. Siempre, ya que son tumores malignos y de mayor agresividad.\nB. Si el tumor es mayor de 2 cm.\nC. Dependiendo del tipo de mutación del gen de MEN1 que presente el paciente.\nD. Solo si crecen y producen sintomatología.\n\n### COMENTARIO\n\nLos tumores neuroendocrinos (TNE) pancreáticos son los segundos tumores en frecuencia en MEN1. Su prevalencia (37-75%) ha aumentado en los últimos años por la mayor sensibilidad de los estudios de imagen, sobre todo la prevalencia de los TNE pancreáticos no funcionantes que se consideran actualmente los tumores pancreáticos más frecuentes en MEN1.\n\nLos TNE pancreáticos no funcionantes no están asociados a ningún síndrome clínico porque habitualmente no secretan ninguna hormona, un tercio de ellos ni siquiera cromogranina A; en otras ocasiones, se detectan niveles elevados de polipéptido pancreático o glucagón que no producen ningún síntoma.\n\nEstos tumores pueden malignizar en aproximadamente el 30% de los pacientes, por lo que dada su frecuencia (40-80%) son la principal causa de mortalidad en los pacientes MEN1 en la actualidad. Se han descrito en pacientes de 12 años; por ello, la Guía Clínica de 2012 recomienda realizar estudios de imagen abdominales a partir de los 10 años.\n\nTratamiento: existe controversia sobre el momento del tratamiento quirúrgico en pacientes asintomáticos. La Guía Clínica de 2012 recomienda la intervención quirúrgica si el tumor es mayor de 1 cm, sobre todo si ha presentado crecimiento en los últimos 6 meses. Por\n---\nMETABOLISMO FOSFOCÁLCICO, TUMORES NEUROENDOCRINOS Y MEN 7\n\nel contrario, en los últimos años se han publicado series retrospectivas de pacientes con síndrome MEN1 que apoyan la actitud más conservadora de intervención quirúrgica solo si los tumores son de 2 cm o más. Esta recomendación está avalada por la sociedad europea (ENETS, European Neuroendocrine Tumor Society) y la norteamericana de tumores neuroendocrinos (NANETS, North American Neuroendocrine Tumor Society) y los grupos francés y holandés de neoplasia endocrina múltiple tipo 1.\n\nReferencias:\n- Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n- Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:1-22.\n- Valdés Gallego N. Manual de Endocrinología y Nutrición (Internet). Capítulo 3. Neoplasia Endocrina Múltiple. Madrid: Sociedad Española de Endocrinología y Nutrición; 2015. Disponible en: https://manual.seen.es\n\n## 43 En el caso anterior, hemos de seguir a esta paciente con vigilancia mediante cribado periódico bioquímico y/o morfológico para detectar:\n\nA. Carcinoma de mama.\nB. Cáncer de tiroides.\nC. Melanoma.\nD. Carcinoma de colon.\n\nCOMENTARIO\n\nEl síndrome de MEN1 está asociado a un mayor riesgo de desarrollo de tumores endocrinos y no endocrinos aparte de los considerados clásicamente (tumores de las glándulas paratiroides, enteropancreáticos e hipofisarios). Estos tumores se han ido describiendo a lo largo de los últimos años y se ha descrito la implicación del gen MEN1 en su patogénesis.\n\nEn 2014 se publicó en el New England Journal of Medicine el mayor riesgo de las mujeres con MEN1 de desarrollar cáncer de mama y a edades más tempranas que la población general. Además, se demostró la implicación del gen MEN1 en la tumorogénesis de estos tumores. Posteriormente, en 2017 se publicó un trabajo del grupo holandés que recomienda comenzar el cribado de cáncer de mama en estas mujeres a los 40 años.\n\nLos pacientes con MEN1 tienen riesgo de desarrollar otros tipos de tumores con el mismo riesgo que la población general, pero no se ha descrito la implicación del gen MEN1 en la tumorogénesis del cáncer de colon, tiroides o melanoma.\n\nReferencias:\n- Dreijerink\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}